Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
1.
Br J Cancer ; 113(2): 321-6, 2015 Jul 14.
Artigo em Inglês | MEDLINE | ID: mdl-26057450

RESUMO

BACKGROUND: Tongue squamous cell carcinoma (TSCC) is increasing in incidence, especially among young patients and preferably females. Infection with human papilloma virus (HPV) has been suggested as a cause of SCC in the head and neck, and the proportion of oropharyngeal cancers caused by HPV has steadily increased. METHODS: Samples from 109 patients with primary TSCC were analysed for the presence of HPV16 by in situ hybridisation and for expression of its surrogate marker p16 and the HPV receptor syndecan-1 by immunhistochemistry. RESULTS: No evidence of HPV16 DNA was observed in the tumours, although one-third showed p16 staining. There was no difference in the expression of the primary HPV receptor, syndecan-1, between TSCC and a group of tonsil SCC. CONCLUSION: Whereas p16 is expressed in some TSCCs, HPV16 is undetectable, therefore, p16 cannot be used as a surrogate marker for high-risk HPV-infection in this tumour. Despite presence of the HPV-receptor syndecan-1 in TSCC, HPV prefers the tonsillar environment. Lack of p16 associates with worse prognosis primarily in patients aged ⩽40 years with tongue SCC. The improved prognosis seen in p16-positive TSCC can be due to induction of a senescent phenotype or an inherent radiosensitivity due to the ability of p16 to inhibit homologous recombination repair.


Assuntos
Carcinoma de Células Escamosas/virologia , Neoplasias de Cabeça e Pescoço/virologia , Papillomavirus Humano 16/isolamento & purificação , Proteínas de Neoplasias/fisiologia , Infecções por Papillomavirus/complicações , Receptores Virais/fisiologia , Sindecana-1/fisiologia , Neoplasias da Língua/virologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/mortalidade , Inibidor p16 de Quinase Dependente de Ciclina , DNA Viral/análise , Feminino , Neoplasias de Cabeça e Pescoço/mortalidade , Humanos , Hibridização In Situ , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/análise , Carcinoma de Células Escamosas de Cabeça e Pescoço , Sindecana-1/análise , Neoplasias da Língua/mortalidade
2.
Oncogene ; 26(3): 382-94, 2007 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-16878156

RESUMO

We show that human osteosarcoma cells (Saos-2) have downregulation of alpha3beta1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The alpha3 gene was silenced in Saos-2 cells causing a low expression of alpha3beta1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on alpha3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the alpha3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREB-binding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the alpha3-integrin promoter downregulation in normal osteoblasts. This downregulation of alpha3beta1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.


Assuntos
Inativação Gênica , Integrina alfa3/genética , Integrina alfa3beta1/metabolismo , Osteossarcoma/metabolismo , Proteínas Proto-Oncogênicas c-myc/metabolismo , Fator de Transcrição YY1/metabolismo , Animais , Sequência de Bases , Fatores de Transcrição de Zíper de Leucina Básica/metabolismo , Western Blotting , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Imunoprecipitação da Cromatina , Colágeno/metabolismo , Regulação para Baixo , Ensaio de Desvio de Mobilidade Eletroforética , Feminino , Imunofluorescência , Humanos , Laminina/metabolismo , Camundongos , Camundongos Nus , Dados de Sequência Molecular , Osteoblastos/citologia , Osteoblastos/metabolismo , Osteossarcoma/genética , Osteossarcoma/patologia , Regiões Promotoras Genéticas/genética , RNA Interferente Pequeno/farmacologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transcrição Gênica , Transfecção , Células Tumorais Cultivadas , Fator de Transcrição YY1/antagonistas & inibidores , Fator de Transcrição YY1/genética
3.
J Exp Clin Cancer Res ; 26(2): 291-2, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17725112

RESUMO

In this manuscript for the first time we describe the concomitant diagnosis of primary renal non-Hodgkin lymphoma (PRL) and of a papillary urothelial cancer in a patient with megaloblastic anemia. PRL is a rare disease, since the kidney is one of the extranodal organs usually not containing lymphoid tissue. The disease usually affects adults with an average age of 60 years and slight male preponderance. Flank pain is the most common presenting symptom and different histologies have been reported. A review of literature indicated that simultaneous diagnosis of PRL and papillary urothelial carcinoma of the urether, makes our case unique. The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy.


Assuntos
Carcinoma Papilar/diagnóstico por imagem , Neoplasias Renais/diagnóstico por imagem , Linfoma não Hodgkin/diagnóstico por imagem , Neoplasias Ureterais/diagnóstico por imagem , Carcinoma Papilar/complicações , Carcinoma Papilar/patologia , Diagnóstico Precoce , Feminino , Humanos , Neoplasias Renais/complicações , Neoplasias Renais/patologia , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/patologia , Tomografia Computadorizada por Raios X , Neoplasias Ureterais/complicações , Neoplasias Ureterais/patologia
4.
Eur J Gynaecol Oncol ; 27(3): 307-9, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16800268

RESUMO

INTRODUCTION: Abdominal scar recurrence of endometrial carcinoma after abdominal total hysterectomy is very rare. We report a case of a 65-year-old woman who had two recurrences in the abdominal incisional scar after total hysterectomy. CASE REPORT: A 65-year-old woman underwent total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy because of well-differentiated endometrial adenocarcinoma (Stage IIB). Thus, the patient was treated by external beam radiotherapy. She developed two recurrences in the abdominal incisional scar two and three years after total hysterectomy, respectively. Surgery plus chemotherapy and surgery plus hormonal therapy were used for treatment of the first and second scar recurrence, respectively. CONCLUSIONS: It is a very intriguing and controversial biologic question how neoplastic cells can implant and grow in an abdominal scar without other concomitant metastases. We report a review of the literature and the possible mechanism of recurrences in laparotomy wounds.


Assuntos
Parede Abdominal , Adenocarcinoma/cirurgia , Cicatriz , Neoplasias do Endométrio/cirurgia , Laparotomia , Recidiva Local de Neoplasia , Inoculação de Neoplasia , Adenocarcinoma/patologia , Idoso , Cicatriz/etiologia , Cicatriz/patologia , Neoplasias do Endométrio/patologia , Feminino , Humanos , Histerectomia
5.
Eur J Gynaecol Oncol ; 27(3): 313-6, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16800270

RESUMO

The term female adnexal tumor of probable Wolffian origin "FATWO" designs this tumor wich arises by the rare persisting remnants of the mesonephric duct (Wolffian duct). About 40 cases have been reported in literature. Few cases of recurrence have been reported, FATWO usually shows no signs of hormonal activity. We report a case of the youngest patient affected by FATWO in October 2002. At laparotomy the left adnexa were deformed by a well-capsulated mass, totally removed and sent to the pathologist with a specimen of peritoneal fluid and of the omentum. The histological examination showed a prevalent tubular structure with focal retiform area, without intraluminal mucines. Immunohistochemical findings of the case reported are similar to those described by other authors, except for inhibin which has not been detected by us. The cytofluorimetry showed the low presence of aneuploid cells, with a very low prolifing component (< 1%).


Assuntos
Doenças dos Anexos/patologia , Neoplasias dos Genitais Femininos/patologia , Ductos Mesonéfricos , Doenças dos Anexos/metabolismo , Adulto , Ligamento Largo , Feminino , Citometria de Fluxo , Neoplasias dos Genitais Femininos/metabolismo , Humanos , Imuno-Histoquímica
6.
Infez Med ; 13(4): 255-8, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16388281

RESUMO

Brucellosis is endemic in the Mediterranean area. In spite of the false negative results, the standard agglutination test remains the routine test for the diagnosis of brucellosis in southern Italy. We present a case of a patient with undulant fever and erythema nodosum-like skin lesions, with negative serum agglutination test, but isolated positivity of the ELISA test for anti-Brucella IgM. A diagnosis of brucellosis for this patient was supported by the anamnestic and clinical data, and by the response to therapy. This case and a review of the literature urge us to consider the ELISA test indispensable for the serological diagnosis of brucellosis.


Assuntos
Brucelose/diagnóstico , Ensaio de Imunoadsorção Enzimática , Eritema Nodoso/diagnóstico , Imunoglobulina M/análise , Adulto , Animais , Brucelose/imunologia , Bovinos , Eritema Nodoso/imunologia , Feminino , Humanos , Imunoglobulina M/imunologia , Valor Preditivo dos Testes
7.
Histol Histopathol ; 12(3): 671-6, 1997 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9225149

RESUMO

By immunohistochemistry, the presence of major iron-binding proteins (lactoferrin, transferrin, ferritin) has been investigated in adenocarcinomas (27 cases), adenosquamous carcinoma (1 case), undifferentiated sarcomatoid carcinoma (1 case) and mucinous adenocarcinomas (3 cases) of the gallbladder 10 samples of chronic lithyasic cholecystitis, 4 adenomyomas and 6 tubulo-villous adenomas have also been studied. In a variable share of adenocarcinomas, a positive immunoreactivity for iron-binding antisera was encountered in the cytoplasm, while tubulo-villous adenomas, adenomyomas and the normal epithelium of the gallbladder were generally unreactive. In carcinomatous lesions, the staining intensity was variable between different cases or individual tumour cells. The production of these iron-binding proteins in the gallbladder carcinoma in itself could be related to a greater availability of iron for metabolic processes in the neoplastic cell; alternatively, the cytoplasmic localization of these substances in carcinomatous elements may be a consequence of a defective or impaired function of iron-binding receptors with a modified degree of transmembranous iron transfer.


Assuntos
Ferritinas/metabolismo , Neoplasias da Vesícula Biliar/metabolismo , Lactoferrina/metabolismo , Transferrina/metabolismo , Adulto , Idoso , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade
8.
J Clin Pathol ; 37(1): 51-5, 1984 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-6323544

RESUMO

An immunoperoxidase staining technique was used for detecting three major iron binding proteins (ferritin, transferrin and lactoferrin) in 40 breast carcinoma cases and six benign breast proliferative lesions. Ferritin staining was detected mainly in connectival stroma and in histiocytes surrounding neoplastic cells. Few and faint ferritin positivities were also detected in neoplastic cells of 20 carcinoma cases. Transferrin was found inconsistently in myoepithelial cells surrounding normal ductules, or around neoplastic ducts of ductal in situ carcinoma. In eight carcinoma cases, transferrin staining was also positive in neoplastic cells. Lactoferrin was detected only in normal breast epithelial cells and in benign breast proliferative lesions. These immunohistochemical findings may suggest that raised serum ferritin concentrations in breast carcinoma patients might be attributed to stromal reaction rather than to tumour synthesis. Transferrin staining of neoplastic cells in these carcinoma cases appears to be very intriguing, particularly since transferrin is considered an obligate requirement for growing cells, and transferrin receptors have been demonstrated only in dividing cells. On the basis of the immunohistochemical data, lactoferrin might be used as a pointer to benign lesions.


Assuntos
Neoplasias da Mama/análise , Ferritinas/análise , Lactoferrina/análise , Lactoglobulinas/análise , Transferrina/análise , Adenocarcinoma Mucinoso/análise , Mama/análise , Doenças Mamárias/metabolismo , Carcinoma/análise , Carcinoma in Situ/análise , Carcinoma Intraductal não Infiltrante/análise , Feminino , Humanos , Técnicas Imunoenzimáticas
9.
Thyroid ; 12(9): 815-21, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12481948

RESUMO

We present a prospective study on the long-term efficacy of percutaneous ethanol injection (PEI) treatment of a large series of symptomatic thyroid cystic nodules (STCN). Ninety-eight patients (72 females and 26 males) were treated. The mean basal volume of the STCN was 35.3 mL. In 92 of 98 patients PEI treatment induced a greater than 50% nodule shrinkage, only 6 of 92 responder patients relapsed at a follow-up of 9 years. Moreover, all the patients had a significant clinical benefit because a significant reduction of the cyst-associated symptoms was recorded. Furthermore, a limited number of sessions was required for the treatment of cysts larger than 40 mL (mean +/- standard deviation [SD]: 2.7 +/- 0.75) demonstrating the feasibility of the procedure also in the treatment of large cysts. In conclusion, PEI is an effective and inexpensive procedure with a high patient compliance and long-lasting effects in the treatment of cysts larger than 40 mL.


Assuntos
Etanol/administração & dosagem , Solventes/administração & dosagem , Nódulo da Glândula Tireoide/tratamento farmacológico , Administração Cutânea , Adolescente , Adulto , Idoso , Cistos/diagnóstico por imagem , Cistos/tratamento farmacológico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Nódulo da Glândula Tireoide/diagnóstico por imagem , Resultado do Tratamento , Ultrassonografia
10.
Anticancer Res ; 24(3b): 1897-900, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15274372

RESUMO

Kaposi's sarcoma (KS) of the tongue is extremely rare in immunocompetent patients. We report a case of KS of the tongue associated with a median rhomboid glossitis. The main clinical, pathological and immunohistochemical features allowed the differential diagnosis.


Assuntos
Glossite/patologia , Sarcoma de Kaposi/patologia , Neoplasias da Língua/patologia , Idoso , Diagnóstico Diferencial , Glossite/complicações , Glossite/diagnóstico , Humanos , Imuno-Histoquímica , Masculino , Sarcoma de Kaposi/complicações , Sarcoma de Kaposi/diagnóstico , Neoplasias da Língua/complicações , Neoplasias da Língua/diagnóstico
11.
Anticancer Res ; 23(5b): 4101-3, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14666608

RESUMO

Canalicular adenoma is an uncommon benign neoplasm that occurs almost exclusively in the upper lip and, very rarely, in other sites. We describe a case arising in the left parotid gland as a firm, painful mass, in order to underline morphological and immunohistochemical findings, particularly in relation to differential diagnosis with low-grade carcinomas of the salivary glands.


Assuntos
Adenoma/patologia , Neoplasias Parotídeas/patologia , Feminino , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade
12.
Anticancer Res ; 23(5b): 4105-8, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14666609

RESUMO

Two cases of Merkel cell carcinoma (MCC) of the head and neck region are reported in order to stress their diversity in morphological, immunohistochemical and clinical findings. The remarkable variability of MCC has been analyzed, particularly in relation to the differential diagnosis and prognostic implications.


Assuntos
Carcinoma de Célula de Merkel/patologia , Neoplasias de Cabeça e Pescoço/patologia , Idoso , Carcinoma de Célula de Merkel/diagnóstico , Carcinoma de Célula de Merkel/metabolismo , Diagnóstico Diferencial , Feminino , Neoplasias de Cabeça e Pescoço/diagnóstico , Neoplasias de Cabeça e Pescoço/metabolismo , Humanos , Imuno-Histoquímica , Masculino
13.
Anticancer Res ; 20(5C): 3919-22, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11268477

RESUMO

A case of benign, cystic intrapulmonary teratoma occurring in the right lobe of a 22-year old female is described with grossly and microscopically findings. The connection between the tumor and the segmental bronchus, together with the absence of germ cell neoplasms in other locations, clearly established the true intrapulmonary nature of the lesion. The unusual finding of thymic tissue within the wall supports the possible origin from the third pharyngeal pouch.


Assuntos
Neoplasias Pulmonares/patologia , Teratoma/patologia , Timo/patologia , Actinas/análise , Adulto , Antígenos CD/análise , Autopsia , Colágeno/análise , Feminino , Humanos , Queratinas/análise
14.
Anticancer Res ; 20(5A): 3301-5, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11062757

RESUMO

The first cyclin dependent kinase inhibitor to be discovered was the p21 cdk interacting protein (a.k.a., WAF1, Cip1, CAP20, Sdi1, mda6). p21 expression may or may not be dependent on p53. This pathway also inhibits DNA replication by merit of p21's interaction with PCNA, but it has also been shown that this same inhibitory interaction with p21 does not affect PCNA DNA repair abilities. We assessed the immunohistochemical expression of p21 protein in 60 curative surgical resected non small cell lung cancers relating it to the expression of PCNA to clarify the contribution of the p21/PCNA pathway to the development of NSCLC. We did not find any relationship between PCNA and p21 expression. This last result may indicate that the mechanism by which PCNA controls the DNA repair is the most important activity of this protein during lung cancer progression and development, compared to its contribution to cell proliferation. In fact, this last event is strongly counteracted by p21 expression, which in this last case works as an inhibitor of PCNA expression. In conclusion this study highlighted the important role of the p21/PCNA pathway in lung carcinogenesis, pointing out the contribution of PCNA to the response to lung aggression and not only it's role as a proliferation index. Therefore, these results offer a background to further study to evaluate potential novel therapeutic approaches to lung cancer treatment.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/metabolismo , Ciclinas/biossíntese , Inibidores Enzimáticos , Neoplasias Pulmonares/metabolismo , Antígeno Nuclear de Célula em Proliferação/biossíntese , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patologia , Inibidor de Quinase Dependente de Ciclina p21 , Humanos , Neoplasias Pulmonares/patologia
15.
Pathol Res Pract ; 192(5): 407-13, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8832744

RESUMO

The amount and distribution of interphase argyrophilic nucleolar organizer regions (AgNORs) was studied in 51 gallbladder surgical specimens including 32 primary carcinomas, 10 adenomas and 9 cases of chronic cholecystitis with calculi. The mean nuclear AgNOR area (NORA) and the AgNOR distribution score (NORDS), i.e. the percentage of cells carrying nucleolar aggregates with more than 6 distinct silver dots, were evaluated in 200 epithelial nuclei per specimen by means of automated image analysis and direct counting respectively. Statistical analysis (variance analysis and Student-Neuman-Keuls' test) performed on the pooled mean AgNOR values showed a significant difference (p < 0.001) between carcinomas and non-carcinomatous lesions. Both NORA and NORDS highly discriminated carcinomas with histopathological grade 4 versus cases with grade 1, 2 or 3 (p < 0.001); a less statistically significative p value (< 0.05) was encountered when NORDS values of well differentiated grade 1 carcinomas and adenomas were compared. The NORA parameter permitted the discrimination of stage IV versus stage I carcinomas (p < 0.001), while carcinomas in stage IV and those in stage II were distinguished with a p < 0.05; the NORDS parameter allowed also to distinguish stage IV from both stage I or II tumours (p < 0.001). Our results indicate that the above-mentioned AgNOR parameters may be utilized as additional, more objective quantitative criteria in the clinical-pathological assessment of the outcome of gallbladder carcinomas.


Assuntos
Carcinoma/patologia , Neoplasias da Vesícula Biliar/patologia , Microscopia de Vídeo/métodos , Estadiamento de Neoplasias/métodos , Região Organizadora do Nucléolo/patologia , Adenoma/patologia , Adulto , Idoso , Colecistite/patologia , Humanos , Pessoa de Meia-Idade , Prata , Coloração e Rotulagem/métodos , Telepatologia/métodos
16.
Nucl Med Commun ; 9(5): 347-56, 1988 May.
Artigo em Inglês | MEDLINE | ID: mdl-2842708

RESUMO

Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85% in the detection of primary ovarian cancers and collections of ascites, and of 84% in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.


Assuntos
Adenocarcinoma Mucinoso/diagnóstico por imagem , Adenocarcinoma Papilar/diagnóstico por imagem , Anticorpos Monoclonais , Imunoglobulina G , Neoplasias Ovarianas/diagnóstico por imagem , Neoplasias Abdominais/diagnóstico por imagem , Neoplasias Abdominais/secundário , Adenocarcinoma Mucinoso/patologia , Adenocarcinoma Papilar/patologia , Adulto , Idoso , Ascite/complicações , Ascite/diagnóstico , Estudos de Avaliação como Assunto , Feminino , Humanos , Radioisótopos do Iodo , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Ovarianas/patologia , Projetos Piloto , Valor Preditivo dos Testes , Estudos Prospectivos , Cintilografia , Fatores de Tempo
17.
In Vivo ; 14(4): 493-8, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10945164

RESUMO

The authors describe a rare case of peritoneal mesothelioma. Cytological, histological and immunohistochemical characterization of the tumor allowed the differential diagnosis from papillary carcinoma and suggested the diagnosis of leiomyoid mesothelioma.


Assuntos
Carcinoma Papilar/secundário , Mesotelioma/patologia , Neoplasias Peritoneais/patologia , Idoso , Ascite , Líquido Ascítico/patologia , Biomarcadores/análise , Biomarcadores Tumorais/análise , Biópsia , Carcinoma Papilar/patologia , Diagnóstico Diferencial , Evolução Fatal , Feminino , Humanos
18.
In Vivo ; 14(4): 487-92, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10945163

RESUMO

A case of rare primary adenocarcinoma of the bulbomembranous portion of the male urethra is presented. The histological and immunohistochemical characteristics of this tumor are identical to those of colon adenocarcinomas. The pathogenesis can be explained either by neoplastic degeneration of globet cells found in the urethral epithelium or by malignant degeneration of persistent glandular elements that are embryonal residues. The patient was successfully treated with transurethral prostatectomy and with a high dose of radiation therapy.


Assuntos
Adenocarcinoma/patologia , Neoplasias do Colo/patologia , Neoplasias Uretrais/patologia , Adenocarcinoma/radioterapia , Adenocarcinoma/cirurgia , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Prostatectomia , Uretra/patologia , Neoplasias Uretrais/radioterapia , Neoplasias Uretrais/cirurgia , Urotélio/patologia
19.
Minerva Gastroenterol Dietol ; 50(4): 339-43, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15788990

RESUMO

Ranitidine may cause liver injuries ranging from transient, subclinical serum transaminases increase every 100-1,000 treated patients to cholestatic hepatitis in less than 1/100,000. Other H2-receptor antagonists are more dangerous: 11 toxic hepatitis cases have been reported as adverse effect after 1 year of marketed ebrotidine. A 75-year-old male with ischemic cardiopathy history was started on an 8 days treatment of oral ranitidine due to pirosis, without any other changes of therapy; 48 h after drug withdrawal, light-coloured stools, dark urine and icteric scleras developed. On hospital admission, 10 days later, physical examination showed slight hepatomegaly and severe jaundice with skin excoriations followed by serum mixed bilirubin further increase and aminotransferases activities mild rise. Total bilirubin peaked at 381.33 mmol/l (5.1-17.1) and progressively returned to normal, after discharge home, in 3 months and now, 1 year later, there is no sign of liver disease. Ultrasonographic biliary anomalies and the most frequent causes of liver damage were excluded. Liver biopsy confirmed ranitidine as the most likely cause of liver toxicity since histological and ultramicroscopical study revealed a drug-induced picture. We report a rare case of intrahepatic cholestasis jaundice related to ranitidine, a widely used drug. Diagnosis would need an ethically unacceptable rechallange test.


Assuntos
Colestase Intra-Hepática/induzido quimicamente , Antagonistas dos Receptores H2 da Histamina/efeitos adversos , Icterícia Obstrutiva/induzido quimicamente , Ranitidina/efeitos adversos , Idoso , Colestase Intra-Hepática/patologia , Humanos , Icterícia Obstrutiva/patologia , Masculino
20.
Presse Med ; 24(26): 1201-6, 1995 Sep 16.
Artigo em Francês | MEDLINE | ID: mdl-7567847

RESUMO

OBJECTIVES: A randomized controlled trial was set up to assess the effect of two different therapy regimens with lymphoblastoid interferon on the treatment and follow-up of patients with chronic C hepatitis. METHODS: Eighty-five patients with chronic hepatitis C were randomized into two treatment groups (n = 30 respectively) and one control group (no treatment: n = 25). In one treatment group patients received three million units of alpha-lymphoblastoid interferon. The other received six million units. RESULTS: A rapid decline in both alanine aminotransferase and aspartataminotransferase levels was seen in most treated patients (a complete response in 51% from group A and 55% from group B; partial response 29% from group A, 25% from group B). In five partial responders and six complete responders from group A and in seven partial responders and six complete responders in group B serum aminotransferase levels returned to baseline values in the follow-up. No change in serum bilirubin, albumin, IgG and prothrombin time during interferon treatment were seen. The histologic staging remained unchanged throughout the entire study. CONCLUSION: alpha-interferon treatment improves the clinical picture, biochemical parameters and histologic pattern in a large percentage of patients with hepatitis C. Long-term remission was seen in only 37% of treated patients. Using six million units of alpha-interferon has not proven to be significantly better than three million units. Protracted treatment for nine months seems to increase the percentage of patients in biochemical and histologic remission.


Assuntos
Antivirais/administração & dosagem , Hepatite C/tratamento farmacológico , Interferon-alfa/administração & dosagem , Adulto , Alanina Transaminase/sangue , Doença Crônica , Método Duplo-Cego , Feminino , Seguimentos , Hepatite C/sangue , Hepatite C/patologia , Humanos , Fígado/patologia , Masculino , Pessoa de Meia-Idade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA